Know Cancer

forgot password

Multicenter Phase II Study of MK-2206 in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma

Phase 2
18 Years
Open (Enrolling)
Recurrent Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx

Thank you

Trial Information

Multicenter Phase II Study of MK-2206 in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma


I. To determine the proportion of patients alive and progression-free at 6 months along with
the confirmed response rate as a dual primary endpoint..


I. To evaluate best response and duration of response for patients treated with MK2206 (Akt
inhibitor MK2206).

II. To evaluate the overall survival and progression-free survival (PFS) of patients treated
with MK2206.

III. To evaluate safety and tolerability of MK2206.


I. To evaluate the pharmacokinetics of MK2206 in Asian patients. II. To study the
pharmacodynamic effect of MK2206 using biomarkers and correlation with cancer-related

OUTLINE: This is a multicenter study.

Patients receive Akt inhibitor MK2206 orally (PO) on days 1, 8, 15, and 22. Courses repeat
every 28 days in the absence of disease progression or unacceptable toxicity.

Patients undergo blood sample collection at baseline and periodically during study for
pharmacogenomic and pharmacokinetic studies.

After completion of study therapy, patients are followed up for up to 3 years.

Inclusion Criteria:

- Histologically or cytologically confirmed non-keratinizing nasopharyngeal carcinoma
that has recurred at locoregional and/or distant sites, and is not amenable to
potentially curative radiotherapy or surgery

- Measurable disease according to the RECIST criteria

- Progressed =< 24 months of receiving one or two prior line(s) of chemotherapy for
recurrent disease, of which at least one line must contain platinum drugs such as
cisplatin, carboplatin or oxaliplatin

- ECOG performance status 0, 1, or 2

- Hemoglobin >= 9 g/dL

- ANC >= 1,500/μL

- Platelet count >= 100,000/μL

- Total bilirubin =< 2.5 times upper limit of normal (ULN)

- ALT =< 2.5 times ULN (=< 5 times ULN for patients with liver metastases)

- Creatinine =< 1.5 times ULN OR creatinine clearance >= 60 mL/min/1.73 m^2

- Ability to understand and the willingness to sign a written informed consent document

- Willingness to donate blood for mandatory correlative research studies

- Negative (serum) pregnancy test done =< 7 days prior to registration, for women of
childbearing potential only

Exclusion Criteria:

- Any of the following

- Chemotherapy =< 4 weeks prior to registration

- Radiotherapy =< 4 weeks prior to registration

- Nitrosoureas or Mitomycin C =< 4 weeks prior to registration

- Those who have not recovered from adverse events due to agents administered more
than 4 weeks earlier

- NOTE: Prior palliative radiotherapy to bone metastases is allowed =< 4 weeks
prior to registration

- Prior investigational agents =< 4 weeks prior to registration

- Symptomatic brain metastases; NOTE: primary nasopharyngeal cancers that directly
invade the skull base and extend into the infratemporal fossa(e) are not regarded as
brain metastases and are not excluded

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to MK-2206 or other agents used in the study

- Prior potent and moderate inhibitors and inducers of CYP3A4 =< 2 weeks prior to

- Drugs that are forbidden, potent inducers of CYP3A4: phenytoin, phenobarbitone,
carbamazepine, barbiturate, rifampicin, St John's Wort.

- Drugs that significantly affect metabolizing activity by way of enzyme
inhibition of CYP3A4: ketoconazole, itraconazole, fluconazole, indinavir,
ritonavir, erythromycin, cimetidine, clarithromycin

- Unwillingness to go off other inducers and inhibitors of CYP3A4 during the first 2
cycles of MK-2206; NOTE: avoiding these drugs is critical during the first 2 cycles
of MK-2206when blood samples are being taken for the correlative study unless there
is an urgent medical need and alternatives are not available

- Poorly controlled diabetes mellitus or insulin controlled diabetes; NOTE: As a
general guide, patients with a fasting glucose level > 150 mg/dL (HbA1c <8%, > 8.3
mmol/L), or a random glucose level of >180mg/dL (> 10 mmol/L) is considered to have
inadequately controlled diabetes and are not eligible for this study; however, such
patients can become eligible in the future if their fasting glucose levels improve
with medical treatment

- QTc prolongation (defined as a QTc interval > 450 msec for males and >470 msec for
females) or other significant ECG abnormalities; NOTE: patients with clinically
significant cardiac conduction abnormalities should be excluded, these include left
bundle branch block (LBBB), 2nd or 3rd degree AV block, bifascicular block, sick
sinus syndrome, Wolff-Parkinson-white syndrome, sinus bradycardia (< 50bpm); however,
patients with asymptomatic right bundle branch block (RBBB) or 1st degree AV block,
in the absence of known cardiac disease (e.g. coronary, valvular) are not excluded

- Uncontrolled intercurrent illness including, but not limited to:

- Ongoing or active infection,

- Symptomatic congestive heart failure,

- Unstable angina pectoris,

- Uncontrolled symptomatic cardiac arrhythmia,

- Psychiatric illness/social situations that would limit compliance with study

- Diagnosed to have any of the following condition(s), and/or have undergone any one of
the following procedure(s) =< 3 months prior to registration:

- Symptomatic thrombotic or hemorrhagic cerebral vascular accident

- Coronary bypass graft

- Angioplasty

- Myocardial infarction

- Patients having continuing >= grade 2 adverse events (excluding alopecia) due to
agents (chemotherapy or radiotherapy) administered > 4 weeks prior to registration
based on Common Terminology Criteria for Adverse Events (CTCAE version 4.0) =< grade

- Any of the following:

- Pregnant women

- Nursing women

- Men or women of childbearing potential who are unwilling to employ adequate

- NOTE: because there is an unknown but potential risk for adverse events in
nursing infants secondary to treatment of the mother with MK-2206, breastfeeding
should be discontinued if the mother is treated with MK-2206; women of
childbearing potential and men must use two forms of contraception (hormonal or
barrier method of birth control; abstinence) prior to study entry and for the
duration of study participation

- HIV-positive patients on combination antiretroviral therapy; NOTE: HIV-positive
patients on combination antiretroviral therapy are ineligible because of the
potential for pharmacokinetic interactions with MK-2206; in addition, these patients
are at increased risk of lethal infections when treated with marrow-suppressive

- Recent major surgery =< 4 weeks prior to registration (excluding the placement of
vascular access), or minor surgery =< 2 weeks prior to registration

- Any condition (e.g., gastrointestinal tract disease resulting in an inability to take
oral medication or a requirement for IV alimentation, prior surgical procedures
affecting absorption) that impairs patients ability to swallow MK-2206 tablets

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Proportion of patients alive and progression-free

Outcome Description:

Evaluated using RECIST version 1.1.

Outcome Time Frame:

6 months

Safety Issue:


Principal Investigator

Brigette Ma

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mayo Clinic


United States: Food and Drug Administration

Study ID:




Start Date:

April 2011

Completion Date:

Related Keywords:

  • Recurrent Squamous Cell Carcinoma of the Nasopharynx
  • Stage IV Squamous Cell Carcinoma of the Nasopharynx
  • Carcinoma
  • Carcinoma, Squamous Cell
  • Head and Neck Neoplasms
  • Nasopharyngeal Neoplasms



Mayo ClinicRochester, Minnesota  55905
University of Iowa Hospitals and ClinicsIowa City, Iowa  52242
Washington University School of MedicineSaint Louis, Missouri  63110
Metro-Minnesota CCOPSt. Louis Park, Minnesota